KCNRG and pneumonitis: Recently, rituximab immunotherapy has been used with relative success to treat pneumonitis in the context of APECED; it leads to a clinical improvement without affecting the production of autoantibodies against potassium channel regulatory protein (KCNRG) (Ferré et al., 2019).